-

Investigation: Prudential May Have Improperly Increased Your Long-Term Care Insurance Premium - Hagens Berman

Attorneys at leading consumer rights law firm believe Prudential may have subjected long-term care policyholders to improper premium increases

SEATTLE--(BUSINESS WIRE)--Attorneys at Hagens Berman are investigating Prudential for allegedly increasing long-term care (LTC) insurance premiums in an improper manner, and the law firm urges Prudential long-term care insureds to learn about their potential rights regarding rate increases.

If you are insured under Prudential long-term care coverage, find out more about Hagens Berman’s investigation. If you are concerned about large rate increases under a different insurer’s long-term care product, we are happy to review your policy to ensure your rights are protected.

The law firm’s investigation indicates Prudential may be improperly increasing long-term care premiums, and attorneys say the company may have also failed to return premiums to certain policyholders.

“Our loved ones seek long-term care insurance to provide security and peace of mind as they age, and many long-term care policyholders are on fixed incomes. Insurance companies can’t be allowed to profit at the expense of vulnerable groups,” said Rob Carey, partner and executive committee member at Hagens Berman and the attorney leading the investigation.

Hagens Berman attorneys believe Prudential may be imposing long-term care premiums at disparate and discriminatory rates, despite this promise to customers, and refusing to return premiums when due.

Learn more about the investigation into Prudential for alleged improper increases of long-term care insurance premiums.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm’s determination has earned it numerous national accolades, awards and titles of “Most Feared Plaintiff’s Firm,” MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at www.hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contacts

Ash Klann
pr@hbsslaw.com
206-268-9363

Hagens Berman

NYSE:PRU

Release Summary
Attorneys at Hagens Berman are investigating Prudential for allegedly increasing long-term care (LTC) insurance premiums in an improper manner.
Release Versions

Contacts

Ash Klann
pr@hbsslaw.com
206-268-9363

Social Media Profiles
More News From Hagens Berman

Hub Group (HUBG) Shares Crater Amid Admitted Improper Accounting – Hagens Berman

SAN FRANCISCO--(BUSINESS WIRE)--Hub Group, Inc. (NASDAQ: HUBG) shares fell over 27% during trading on Feb. 6, 2026, after the company filed a report with the SEC that its quarterly reports going back to March 31, 2025, “should no longer be relied upon.” These events prompted Hagens Berman, a national shareholder rights law firm, to investigate whether Hub Group may have intentionally misled investors about whether its financial statements are consistent with relevant accounting rules. The firm...

Hagens Berman: Lawsuit Details Excessive Harassment and Employment Retaliation at Snohomish County Juvenile Detention Center

SEATTLE--(BUSINESS WIRE)--Snohomish Co. has been sued for retaliation after a former officer reported harassment at Denney Juvenile Justice Center, according to Hagens Berman....

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA had warned the company “on several occasions” not to submit its application for relacorilant, its proposed treatment for hypercortisolism. The report sent Corcept shares down, wiping ou...
Back to Newsroom